Ferdi Öztürk
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Ferdi Öztürk has a total of 29 co-authors. Here are the top co-authors by number of shared publications:
- Hayriye Sarıcaoğlu
Department of Dermatology, Faculty of Medicine, Bursa Uludag University, Bursa 16059, Türkiye
6 shared publications - Şaduman Balaban Adım
Department of Pathology, Bursa Uludag University Faculty of Medicine, BURSA, TURKEY
3 shared publications Kenan Aydoğan
Department of Dermatology and Venereology Bursa Uludag University Faculty of Medicine Bursa Turkey
2 shared publications- Yunus Toso
Department of Dermatology, Bursa Uludag University Faculty of Medicine, Bursa, Turkey
2 shared publications - Batuhan Mustafa Demir
Department of Dermatology and Venereology Bursa Uludag University School of Medicine Bursa Turkey
1 shared publication - Beyhan Cengiz Özyurt
Celal Bayar University, Faculty of Medicine, Department of Public Health, Manisa, Turkey
1 shared publication
Latest Publications
- Open Access
- 13 October 2026
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 15 (20) , 7890
Changes in Quality of Life After Treatment for Non-Melanoma Skin Cancer: A Prospective Cohort Study
Background/Objectives: Non-melanoma skin cancer (NMSC), particularly basal cell carcinoma (BCC) and squamous cell carcinoma (SCC), may adversely affect quality of life (QoL), especially in cosmetically sensitive areas. This study aimed to identify factors associated with QoL in patients with NMSC and to evaluate changes in dermatology- and skin cancer-specific QoL following treatment. Methods: This prospective study included 169 patients with NMSC evaluated at baseline and 3 months after treatment using the Dermatology Life Quality Index (DLQI) and Skin Cancer Quality of Life Impact Tool (SCQOLIT). Factors associated with baseline QoL and changes according to treatment modality and histological subtype were analysed. Results: The mean age was 69.2 ± 11.85 years; 82.8% had BCC and 17.2% had SCC. Mean DLQI scores decreased from 2.29 ± 2.81 to 0.34 ± 0.75 and SCQOLIT scores from 4.78 ± 5.53 to 1.20 ± 1.76 at 3 months (both p < 0.001). Lower educational level was associated with higher baseline DLQI scores, whereas younger age and higher socioeconomic status were associated with higher and lower baseline SCQOLIT scores, respectively; these associations persisted in sensitivity analyses. The associations of younger age, female sex, and SCC histology with higher DLQI scores were less robust. SCC patients had higher baseline DLQI scores than BCC patients (3.66 ± 4.82 vs. 2.01 ± 2.10, p = 0.040), but this difference was no longer statistically significant at 3 months. QoL improved following both surgical and medical treatment, with no significant differences in the magnitude of improvement among surgical or medical treatment types. Conclusions: QoL improved significantly within 3 months after NMSC treatment. Different factors were associated with baseline DLQI and SCQOLIT scores, suggesting that these instruments may capture complementary aspects of QoL. Their combined use may provide a more comprehensive assessment of patients with NMSC.
- 13 October 2026
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 15 (20) , 7890
Open AccessChanges in Quality of Life After Treatment for Non-Melanoma Skin Cancer: A Prospective Cohort Study
Background/Objectives: Non-melanoma skin cancer (NMSC), particularly basal cell carcinoma (BCC) and squamous cell carcinoma (SCC), may adversely affect quality of life (QoL), especially in cosmetically sensitive areas. This study aimed to identify factors associated with QoL in patients with NMSC and to evaluate changes in dermatology- and skin cancer-specific QoL following treatment. Methods: This prospective study included 169 patients with NMSC evaluated at baseline and 3 months after treatment using the Dermatology Life Quality Index (DLQI) and Skin Cancer Quality of Life Impact Tool (SCQOLIT). Factors associated with baseline QoL and changes according to treatment modality and histological subtype were analysed. Results: The mean age was 69.2 ± 11.85 years; 82.8% had BCC and 17.2% had SCC. Mean DLQI scores decreased from 2.29 ± 2.81 to 0.34 ± 0.75 and SCQOLIT scores from 4.78 ± 5.53 to 1.20 ± 1.76 at 3 months (both p < 0.001). Lower educational level was associated with higher baseline DLQI scores, whereas younger age and higher socioeconomic status were associated with higher and lower baseline SCQOLIT scores, respectively; these associations persisted in sensitivity analyses. The associations of younger age, female sex, and SCC histology with higher DLQI scores were less robust. SCC patients had higher baseline DLQI scores than BCC patients (3.66 ± 4.82 vs. 2.01 ± 2.10, p = 0.040), but this difference was no longer statistically significant at 3 months. QoL improved following both surgical and medical treatment, with no significant differences in the magnitude of improvement among surgical or medical treatment types. Conclusions: QoL improved significantly within 3 months after NMSC treatment. Different factors were associated with baseline DLQI and SCQOLIT scores, suggesting that these instruments may capture complementary aspects of QoL. Their combined use may provide a more comprehensive assessment of patients with NMSC.
- Open Access
- 8 September 2026
- Published by Medical Journals Sweden AB in Acta Dermato-Venereologica
- Vol. 106
Panniculitis-like T-cell Lymphoma: Two Different Diseases and Same Imitator
- 8 September 2026
- Published by Medical Journals Sweden AB in Acta Dermato-Venereologica
- Vol. 106
Open AccessPanniculitis-like T-cell Lymphoma: Two Different Diseases and Same Imitator
- 9 April 2026
- Published by Elsevier in Diagnostic Microbiology and Infectious Disease
- Vol. 116 (1) , 117411
Chromoblastomycosis caused by Fonsecaea pedrosoi: The first molecularly confirmed case from Türkiye
- 9 April 2026
- Published by Elsevier in Diagnostic Microbiology and Infectious Disease
- Vol. 116 (1) , 117411
Chromoblastomycosis caused by Fonsecaea pedrosoi: The first molecularly confirmed case from Türkiye
- Open Access
- 30 January 2026
- Published by Mattioli1885 in Dermatology Practical & Conceptual
- Vol. 16 (1) , 6961
Clinical and Histopathological Characteristics of Prurigo Pigmentosa: A Case Series
Introduction: Prurigo pigmentosa (PP) is a rare inflammatory skin disease, first described in 1971 in Japan. The condition is characterized by the abrupt appearance of pruritic, erythematous, maculopapular lesions that typically resolve within several days to weeks, resulting in reticulated hyperpigmentation. Objective: This study aimed to retrospectively evaluate six cases of prurigo pigmentosa in light of clinical and histopathological features and treatment responses. Methods: This retrospective study was performed at the Department of Dermatology, Bursa Uludag University Faculty of Medicine, Bursa, Türkiye, from 2022 to 2025. Six patients were included in the study, and their demographic characteristics, presenting complaints, clinical and histopathological findings, laboratory results, and treatment responses were assessed. Results: Six patients with prurigo pigmentosa were evaluated. All presented with symmetrical, pruritic erythematous eruptions on the trunk and back. Three had a history of ketogenic diet or rapid weight loss. Five patients received oral doxycycline (100–200 mg/day) and demonstrated marked clinical improvement. One patient initially treated with corticosteroids showed worsening and was switched to doxycycline. Histopathology revealed spongiotic dermatitis (N=3), eosinophilic infiltration (N=2), and interface dermatitis (N=1). Elevated serum IgE levels were detected in two cases. Conclusion: In conclusion, prurigo pigmentosa should be suspected in young patients with symmetric pruritic eruptions and a history of ketosis. Awareness of its variable histopathological findings and its strong association with dietary or metabolic triggers is essential to timely diagnosis. The rapid and consistent response to tetracycline-class antibiotics, particularly doxycycline, underscores their value as both a diagnostic aid and a preferred therapeutic option.
- 30 January 2026
- Published by Mattioli1885 in Dermatology Practical & Conceptual
- Vol. 16 (1) , 6961
Open AccessClinical and Histopathological Characteristics of Prurigo Pigmentosa: A Case Series
Introduction: Prurigo pigmentosa (PP) is a rare inflammatory skin disease, first described in 1971 in Japan. The condition is characterized by the abrupt appearance of pruritic, erythematous, maculopapular lesions that typically resolve within several days to weeks, resulting in reticulated hyperpigmentation. Objective: This study aimed to retrospectively evaluate six cases of prurigo pigmentosa in light of clinical and histopathological features and treatment responses. Methods: This retrospective study was performed at the Department of Dermatology, Bursa Uludag University Faculty of Medicine, Bursa, Türkiye, from 2022 to 2025. Six patients were included in the study, and their demographic characteristics, presenting complaints, clinical and histopathological findings, laboratory results, and treatment responses were assessed. Results: Six patients with prurigo pigmentosa were evaluated. All presented with symmetrical, pruritic erythematous eruptions on the trunk and back. Three had a history of ketogenic diet or rapid weight loss. Five patients received oral doxycycline (100–200 mg/day) and demonstrated marked clinical improvement. One patient initially treated with corticosteroids showed worsening and was switched to doxycycline. Histopathology revealed spongiotic dermatitis (N=3), eosinophilic infiltration (N=2), and interface dermatitis (N=1). Elevated serum IgE levels were detected in two cases. Conclusion: In conclusion, prurigo pigmentosa should be suspected in young patients with symmetric pruritic eruptions and a history of ketosis. Awareness of its variable histopathological findings and its strong association with dietary or metabolic triggers is essential to timely diagnosis. The rapid and consistent response to tetracycline-class antibiotics, particularly doxycycline, underscores their value as both a diagnostic aid and a preferred therapeutic option.
- Open Access
- 28 November 2025
- Published by Wiley in Journal of Cosmetic Dermatology
- Vol. 24 (12) , e70577
A Rare Clinical Pattern: Acquired Dermal Melanocytosis of Nose
- 28 November 2025
- Published by Wiley in Journal of Cosmetic Dermatology
- Vol. 24 (12) , e70577
Open AccessA Rare Clinical Pattern: Acquired Dermal Melanocytosis of Nose
- Open Access
- 22 August 2025
- Published by Springer Nature in Cureus
- Vol. 17 (8) , e90783
Quality of Life Assessment in Non-melanoma Skin Cancers and Comparison of the Quality of Life Between Psoriasis and Vitiligo Patients
Objective Despite the increase in incidence of non-melanoma skin cancers (NMSC), deaths are relatively rare. The goal of treatment is to prevent the recurrence of the disease and to increase the quality of life (QoL). The QoL and the cost of treatment are becoming more important treatment goals, as nowadays NMSC are rarely life-threatening. This study aims to assess and compare the QoL in patients with NMSC, psoriasis, and vitiligo using three validated QoL instruments. Methods A total of 150 patients were included in this study, with 50 patients each diagnosed with NMSC, psoriasis, and vitiligo. The QoL was assessed using the European Organization for Research and Treatment of Cancer Core QoL Questionnaire (EORTC QLQ-C30), the Dermatology Life Quality Index (DLQI), and the World Health Organization Quality of Life Scale Short Form (WHOQOL-BREF). Sociodemographic data and disease severity were also recorded. Results The study found that NMSC and psoriasis patients had similar QoL scores, with both groups showing more significant impairment in QoL than vitiligo patients. Psoriasis patients experienced greater deterioration in daily activities and personal relationships, while QoL in work, school, and treatment domains was worse in both NMSC and psoriasis patients compared to vitiligo patients. A negative correlation was observed between disease duration and the physical health domain subscale of the WHOQOL-BREF, as well as the work and school subscale of the DLQI, in vitiligo patients; and between disease duration and the work and school subscale of the DLQI in NMSC patients. Conclusion The findings underscore the significant impact of NMSC on patients’ QoL, highlighting the importance of comprehensive management strategies in these conditions. The similarity in QoL scores obtained across all groups using DLQI and WHOQOL-BREF suggests that the WHOQOL-BREF, a general health QoL scale, can be effectively used alongside the DLQI, a dermatology-specific QoL scale, to assess QoL in dermatologic diseases.
- 22 August 2025
- Published by Springer Nature in Cureus
- Vol. 17 (8) , e90783
Open AccessQuality of Life Assessment in Non-melanoma Skin Cancers and Comparison of the Quality of Life Between Psoriasis and Vitiligo Patients
Objective Despite the increase in incidence of non-melanoma skin cancers (NMSC), deaths are relatively rare. The goal of treatment is to prevent the recurrence of the disease and to increase the quality of life (QoL). The QoL and the cost of treatment are becoming more important treatment goals, as nowadays NMSC are rarely life-threatening. This study aims to assess and compare the QoL in patients with NMSC, psoriasis, and vitiligo using three validated QoL instruments. Methods A total of 150 patients were included in this study, with 50 patients each diagnosed with NMSC, psoriasis, and vitiligo. The QoL was assessed using the European Organization for Research and Treatment of Cancer Core QoL Questionnaire (EORTC QLQ-C30), the Dermatology Life Quality Index (DLQI), and the World Health Organization Quality of Life Scale Short Form (WHOQOL-BREF). Sociodemographic data and disease severity were also recorded. Results The study found that NMSC and psoriasis patients had similar QoL scores, with both groups showing more significant impairment in QoL than vitiligo patients. Psoriasis patients experienced greater deterioration in daily activities and personal relationships, while QoL in work, school, and treatment domains was worse in both NMSC and psoriasis patients compared to vitiligo patients. A negative correlation was observed between disease duration and the physical health domain subscale of the WHOQOL-BREF, as well as the work and school subscale of the DLQI, in vitiligo patients; and between disease duration and the work and school subscale of the DLQI in NMSC patients. Conclusion The findings underscore the significant impact of NMSC on patients’ QoL, highlighting the importance of comprehensive management strategies in these conditions. The similarity in QoL scores obtained across all groups using DLQI and WHOQOL-BREF suggests that the WHOQOL-BREF, a general health QoL scale, can be effectively used alongside the DLQI, a dermatology-specific QoL scale, to assess QoL in dermatologic diseases.
- Open Access
- 1 May 2023
- Published by Scientific Scholar in Indian Journal of Dermatology, Venereology and Leprology
- Vol. 89 (6) , 1-3
Acrodermatitis dysmetabolica with argininosuccinate lyase deficiency
- 1 May 2023
- Published by Scientific Scholar in Indian Journal of Dermatology, Venereology and Leprology
- Vol. 89 (6) , 1-3
Open AccessAcrodermatitis dysmetabolica with argininosuccinate lyase deficiency